Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study
Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study
Arangassery Rosemary Bastian, Benoît Callendret, Esther Heijnen, Edmund Omoruyi et al.
Citations
3 citations
Journal
Vaccine
Topics
Respiratory viral infections research
Field-Weighted Citation Impact (FWCI)
1.16
article
Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study
Arangassery Rosemary Bastian, Benoît Callendret, Esther Heijnen, Edmund Omoruyi, Jeffrey B. Rosen, Roy van Heesbeen, Christy Comeaux
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
VaccineVol. 42(26)
Institutions
Janssen (Belgium) (BE), Alliance for Multispecialty Research (United States) (US), Janssen (Netherlands) (NL)